Canadian Rx Imports Would Supply 10% Of U.S. Market, Caremark Exec Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The limited supply of drugs coming from Canada under a legalized importation system would have little impact on U.S. prices, Caremark CEO Crawford says at PCMA annual meeting. Importation would require PBMs to decide how to distribute lower-priced Canadian products among their clients, he says.